Angiotech Pharmaceuticals (ANP.TO) Buy, Sell…

Angiotech Pharmaceuticals (ANP.TO)

0.00

-0.00 (0.00%)

2 watching

TOP PICK

Has real earnings that are identifiable. Could see them making $0.35US this year and growing to $0.80US next year. Market share is back again in spite of the recall troubles they experienced. Looking to diversify the stent further away from the heart.

DON'T BUY

There should be some recovery and show that they have good products coming out. Do not rush to own the stocks.

DON'T BUY

To tell when a stock has bottomed, you need to see more trading at the low level indicating that the sell off is over. Stock is on a negative trend.

BUY

Had some troubles along with Boston Scientific with stent recalls. FDA is allowing them to keep stents three months longer which created a bit of a rally. Reasonable value at this price.

TOP PICK

Feels they handled their recent problems extremely well. Have quite a good product mix going forward.

DON'T BUY

A difficult one. A clever Company and an important one. Very deeply based on the stent business.

WAIT

Got knocked down because of a short term recall on Boston Scientific stents. A short-term problem. Wait and see.

DON'T BUY

Boston Scientific just did a recall on 85,000 stents. Nothing wrong with the Angiotech product, but their partner is having a problem, so at this point it's a gamble.

TRADE

The market has been hurting them because they have not branched out into other areas. The recall of Boston Scientific's stent has also hurt.

BUY

Built a big base from 2000 into 2003 and then took off but at $40 the stock started to weaken. In the minor downtrend. Support will probably come at the $22/23 so you could start buying.

DON'T BUY

Prefers businesses with as much visibility as possible so they can get their minds around. Has done an amazing job. Brutally competitive market. Prefers companies with more diversification.

TOP PICK

Price has dropped and looks at this as an opportunity. Competition is not strong. Lots of cash. Well-positioned.

TRADE

The big question is, Will their stent covering continue to hold a major share of the market.

DON'T BUY

Having Boston Scientific involved and Johnson and Johnson having problems with their stent, is already priced into the stock.

HOLD

Doesnt know if it's a good point of entry. A single product company. Story is well known.

Showing 61 to 75 of 140 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Angiotech Pharmaceuticals (ANP.TO)